|1.||Matsumura, Yasuhiro: 4 articles (06/2014 - 05/2008)|
|2.||Matsumura, Y: 2 articles (09/2006 - 04/2005)|
|3.||Kimura, Masami: 1 article (08/2012)|
|4.||Ikeda, Ryuji: 1 article (08/2012)|
|5.||Shimada, Yasuhiro: 1 article (08/2012)|
|6.||Yoshikawa, Takaki: 1 article (08/2012)|
|7.||Hamaguchi, Tetsuya: 1 article (08/2012)|
|8.||Tsuji, Yasushi: 1 article (08/2012)|
|9.||Chin, Keisho: 1 article (08/2012)|
|10.||Yamaguchi, Kensei: 1 article (08/2012)|
|1.||Stomach Neoplasms (Stomach Cancer)
05/22/2008 - "A phase 2 study of a PTX incorporated micelle, NK105, against stomach cancer is also underway."
08/01/2012 - "This study aimed to evaluate the efficacy and safety of NK105 in patients with advanced gastric cancer after failure of first-line chemotherapy. "
08/01/2012 - "Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer."
07/01/2012 - "The present study evaluated the effects of intraperitoneal administration of NK105, a paclitaxel-incorporating micellar nanoparticle, which has been shown to have a remarkable effect in a mouse model of gastric cancer. "
12/01/2008 - "A Phase 2 study of a paclitaxel-incorporated micelle, NK105, against stomach cancer is also underway."
07/01/2012 - "Moreover, intraperitoneal NK105 significantly reduced the size of subcutaneously inoculated tumors, whereas no such effect was seen with PTX-Cre. "
06/01/2014 - "In this paper, preclinical and clinical studies of NK105, NC-6004, cisplatin incorporating micelle, NC-6300, epirubicin incorporating micelle and the concept of cancer stromal targeting therapy using nanoparticles and monoclonal antibodies against cancer related stromal components are reviewed. "
07/01/2012 - "Intraperitoneal NK105 significantly reduced peritoneal tumors in vivo compared with the conventional paclitaxel formulation of paclitaxel solubilized in Cremophor EL and ethanol (PTX-Cre). "
|3.||Lewis Lung Carcinoma
|5.||Colorectal Neoplasms (Colorectal Cancer)
04/11/2005 - "NK105 showed significantly potent antitumour activity on a human colorectal cancer cell line HT-29 xenograft as compared with PTX (P<0.001) because the enhanced accumulation of the drug in the tumour has occurred, probably followed by its effective and sustained release from micellar nanoparticles. "
|5.||Ethanol (Ethyl Alcohol)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)